The influence of beta-adrenoblocking therapy on the markers of systemic inflammation in patients with acute coronary syndrome

• Published in: Klinicheskaia meditsina Vol. 89; no. 4; p. 56
• Main Authors: Sisakian, A S, Davtian, A R, Pepoian, S K, Oganesian, A S
• Format: Journal Article
• Language: Russian
• Published: Russia (Federation) 2011
• Subjects: Acute Coronary Syndrome - blood; Acute Coronary Syndrome - drug therapy; Adrenergic beta-1 Receptor Antagonists - therapeutic use; Aged; Biomarkers - blood; C-Reactive Protein - analysis; Ceruloplasmin - analysis; Female; Haptoglobins - analysis; Humans; Inflammation - blood; Interleukin-4 - blood; Interleukin-8 - blood; Male; Metoprolol - therapeutic use
• ISSN: 0023-2149

The study was designed to estimate activity of a series of anti-inflammatory markers (C-reactive protein (CRP), ceruloplasmin, haptoglobulin, interleukin (IL)-4, and IL-8) in the acute phase of acute coronary syndrome (ACS) and effect of beta-adrenoblocking therapy on their activity. The patients were divided into 2 groups: one was treated with beta-blocker metoprolol tartrate as a main component of ACS pharmacotherapy (n = 30), the other included the patients with absolute contraindications to bena-adrenoblockers (n = 15). Otherwise, patients of both groups received standard antianginal therapy including nitrates, anticoagulants, ACE inhibitors, and statins. The frequency of prescription of these drugs and coronary angioplasty was comparable in both groups. It was shown that patients with ACS have elevated levels of CRP, haptoglobulin and prooxidant marker ceruloplasmin.